Italian
researchers say that women who are turning from the use of traditional
treatment for breast cancer called tamoxifen to a new type of therapy
called aromatase inhibitors live longer.
She says the study published in the Journal of Cancer to the evidence to suggest that the new drug safer in addition to the fact that symptoms are less side effects than conventional medicine.
Says Dr. Lauren Cassell from the Linux Hill Hospital in New York said the research changed the way doctors treat patients with breast cancer after surgical removal of the tumor process.
"If the patient is used, we now replace tamoxifen treatment, aromatase inhibitors either if they had newly diagnosed, the treatment is aromatase inhibitors instead of tamoxifen directly."
However, tamoxifen remains the main option for young women who suffer from cancer.
"Aromatase inhibitors are used only with women who despair over age."
The use of tamoxifen has spread when it is proven that he reduces the likelihood of recurrence of cancer by up to 50% as it is a plain disk abuse.
However, tamoxifen increased the contrast in the risk of death due to blood clots and uterine cancer.
Then came a new type of aromatase inhibitor called Eladih.
Dr. Franco Bockardo of the Italian National Center for Cancer Research and the University of Genoa, he and his colleagues have given the two studies Hmmelta 828 women.
Half of these women may be taking tamoxifen for five years as was the method of treatment for abuse by half with tamoxifen then aromatase inhibitors have turned to when they are discovered after two to three years.
He Bockardo that women who have had to change therapy were less likely to die due to breast cancer or side effects.
The Germans scientists have already mentioned that similar discoveries in the research was published last November.
And produces many pharmaceutical companies aromatase inhibitors under various brand names such as anastrozole, which is produced by AstraZeneca and a drug produced by Pfizer Aromasen.
Either tamoxifen who shall cease production of the hormone estrogen, which helps the growth of cancer in some cases.
Tamoxifen is sold under the name Commercial Nulfadicks but are marketed through a variety of public companies.
The breast cancer is the leading cause of mortality of women in the United States comes in second place for diseases that cause of death after lung cancer.
According to the American Cancer Society, the 200,000 people infected with this type of cancer each year with almost 40,000 of them die from the disease annually.
She says the study published in the Journal of Cancer to the evidence to suggest that the new drug safer in addition to the fact that symptoms are less side effects than conventional medicine.
Says Dr. Lauren Cassell from the Linux Hill Hospital in New York said the research changed the way doctors treat patients with breast cancer after surgical removal of the tumor process.
"If the patient is used, we now replace tamoxifen treatment, aromatase inhibitors either if they had newly diagnosed, the treatment is aromatase inhibitors instead of tamoxifen directly."
However, tamoxifen remains the main option for young women who suffer from cancer.
"Aromatase inhibitors are used only with women who despair over age."
The use of tamoxifen has spread when it is proven that he reduces the likelihood of recurrence of cancer by up to 50% as it is a plain disk abuse.
However, tamoxifen increased the contrast in the risk of death due to blood clots and uterine cancer.
Then came a new type of aromatase inhibitor called Eladih.
Dr. Franco Bockardo of the Italian National Center for Cancer Research and the University of Genoa, he and his colleagues have given the two studies Hmmelta 828 women.
Half of these women may be taking tamoxifen for five years as was the method of treatment for abuse by half with tamoxifen then aromatase inhibitors have turned to when they are discovered after two to three years.
He Bockardo that women who have had to change therapy were less likely to die due to breast cancer or side effects.
The Germans scientists have already mentioned that similar discoveries in the research was published last November.
And produces many pharmaceutical companies aromatase inhibitors under various brand names such as anastrozole, which is produced by AstraZeneca and a drug produced by Pfizer Aromasen.
Either tamoxifen who shall cease production of the hormone estrogen, which helps the growth of cancer in some cases.
Tamoxifen is sold under the name Commercial Nulfadicks but are marketed through a variety of public companies.
The breast cancer is the leading cause of mortality of women in the United States comes in second place for diseases that cause of death after lung cancer.
According to the American Cancer Society, the 200,000 people infected with this type of cancer each year with almost 40,000 of them die from the disease annually.
ليست هناك تعليقات:
إرسال تعليق